A clinician-guided approach ensures the therapy aligns with your physiology, current health status, and goals
Fat Metabolism Stimulates lipolysis , breaking down triglycerides in adipose tissue Reduces fat mass, especially visceral fat 3
Side-by-Side: DAC vs No-DAC | Side Effect | DAC | No-DAC | |---|---|---| | Flushing | Moderate | Mild | | Headache | Mild | Mild | | Water retention | Mild to moderate | Minimal | | Tingling | Reported more | Reported less | | Vivid dreams | Reported less | Reported more | | Insulin sensitivity over time | Higher theoretical concern | Lower | And for the record, here's what CJC-1295 does not typically cause at compounded doses: significant cortisol elevation, significant prolactin elevation, severe hunger spikes (that's GHRP-6's territory), mood changes, acute hypoglycemia, or acromegalic changes
Crowe FL, Key TJ, Allen NE, Appleby PN, Roddam A, Overvad H, Grnbaek H, Tjnneland A, Halkjaer J, Dossus L, Boeing H, Krger J, Trichopoulou A, Dilis V, Trichopoulos D, Boutron-Ruault MC, De Lauzon B, Clavel-Chapelon F, Palli D, Berrino F, Panico S, Tumino R, Sacerdote C, Bueno-de-Mesquita HB, Vrieling A, van Gils CH, Peeters PH, Gram IT, Skeie G, Lund E: The association between diet and serum concentrations of IGF-I, IGFBP-1, IGFBP-2, and IGFBP-3 in the European Prospective Investigation into Cancer and Nutrition
